1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Amed Co., Ltd.

Amed Co., Ltd.

TTPEX:7575
11.00
TWD
+0.30
(+2.80%)
867.00MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14.18
15.84
18.64
22.99
25.46
27.17
27.4
- -
Basic EPS, GAAP
0.78
1.2
1.66
2.58
3.06
1.84
1.19
- -
Free Cash Flow per Basic Share
0.29
1.05
-0.59
0.83
2.56
-5.79
-0.28
- -
Dividend per Share
- -
- -
- -
- -
- -
2.5
- -
- -
Book Value per Share
5.71
6.91
8.57
11.14
14.2
13.54
13.23
13.23
Tangible Book Value per Share
1.3
2.94
4.95
8.17
11.54
11.13
11.09
11.09
Basic Weighted Avg Shares
29
30
30
30
30
30
30
30
Sales/Revenue/Turnover
414
475
559
690
764
815
822
- -
Operating Margin (%)
8.42
12.15
13.24
16.25
16.16
10.81
9.29
- -
Depreciation Expense
30
28
31
33
28
37
39
- -
Net Income, GAAP
23
36
50
77
92
55
36
- -
Effective Tax Rate (%)
31.32
32.93
28.72
26.68
24.97
34.6
35.95
- -
Profit Margin (%)
5.51
7.6
8.9
11.2
12.01
6.77
4.35
- -
Working Capital
-6
22
53
109
183
140
90
90
LT Debt
131
120
161
142
145
343
295
295
Total Equity
171
207
257
334
426
406
397
397
Return on Invested Capital (%)
- -
8.19
9.94
13.15
13.76
7.1
5.19
- -
Return on Capital (%)
- -
8.61
10.38
13.8
14.77
7.61
4.67
- -
Return on Common Equity (%)
- -
19.08
21.42
26.13
24.12
13.27
8.91
- -

Capital Structure

TWD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
166
225
256
LT Borrowings
333
310
287
LT Finance Leases
10
6
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
1,259
882
867

Working Capital

TWD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
503
528
511
Cash, Cash Equivalents & STI
87
104
79
Accounts Receivable, Net
201
188
199
Inventories
166
205
202
Total Current Liabilities
362
436
420
Payables & Accruals
- -
- -
- -
ST Debt
166
225
256
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.91%
-2.27%
Free Cash Flow
- -
-122.01%
-95.24%
Net Income, GAAP
- -
7.36%
-35.17%
Sales/Revenue/Turnover
- -
11.87%
0.85%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
764
2024
- -
- -
815
2025
- -
- -
822

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
3.06
2024
- -
- -
1.84
2025
- -
- -
1.19

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
2.5
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yao Chien Wang
Full Time Employees
175
Sector
Health technology
Industry
Medical specialties
Address
No.14-1, Wuquan 7th Road New Taipei TP Taiwan 24890
IPO Date
Jun 24, 2022
Website
amed.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Amed Co., Ltd. Amed Co., Ltd. engages in the research, development, manufacture, and trading of medical equipment primarily focused on wound care and pain management solutions in Taiwan. The company offers wound care dressing products under the HERADERM brand name; negative pressure wound therapy systems providing 24-hour oxygen supply to wounds under the Genadyne brand name; wound treatment systems under the Natrox brand name; 7-day long-acting pain reliever injections under the Naldebain brand name; pressure injectable implantable port kits under the POLYSITE brand; and universal linear cutting staplers under the easyEndo brand name. Founded in 2008 and headquartered at No.14-1, Wuquan 7th Road, Wugu District, New Taipei City, Taiwan, Amed Co., Ltd. operates within the healthcare sector, specifically medical instruments and supplies, serving domestic markets including medical centers and regional hospitals with approximately 165 employees. The company listed on the Taipei Exchange in August 2020 under ticker 7575 with an ISIN of TW0007575B17 and maintains a contributed capital of NT$300 million. Recent developments include expansions in product applications, such as new HERADERM dressing products broadening scope as of November 2021, alongside ongoing innovations in orthopedic surgery care and specialized wound management presentations.